|
Systemic Scleroderma
|
0.320 |
Biomarker
|
disease |
BEFREE |
Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis via Repression of Proangiogenic Factors.
|
27482699 |
2016 |
|
Systemic Scleroderma
|
0.320 |
Biomarker
|
disease |
BEFREE |
We previously identified CYR61 as a histone deacetylase 5 (HDAC-5)-repressed gene in systemic sclerosis (SSc; scleroderma) endothelial cells (ECs).
|
30884213 |
2019 |
|
Major Depressive Disorder
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Recently, we could distinguished patients with major depressive disorder (MDD) from nonpsychiatric controls with high accuracy using a panel of five gene expression markers (<i>ARHGAP24, HDAC5, PDGFC, PRNP</i>, and <i>SLC6A4</i>) in leukocyte.
|
28260899 |
2017 |
|
Major Depressive Disorder
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest the alteration of HDAC5 and CREB gene expression in the systemic pathophysiology of major depression.
|
17258370 |
2007 |
|
Unipolar Depression
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest the alteration of HDAC5 and CREB gene expression in the systemic pathophysiology of major depression.
|
17258370 |
2007 |
|
Cocaine Dependence
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
A gene network approach showed that the EHMT1, EHMT2, MAPK1, MAPK3, MAP2K1, and HDAC5 genes, which are involved in transcription and chromatin regulation cellular signaling pathways, were also associated with cocaine dependence.
|
31116258 |
2020 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
A comparative microarray analysis demonstrated a genome wide cooperative effect of HDAC5 and LSD1 on cancer-related gene expression. shRNA knockdown and sulforaphane inhibition of HDAC5/LSD1 exhibited similar effects on expression of HDAC5/LSD1 target genes.
|
29633255 |
2018 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Our study suggested that knockdown of HDAC5 could inhibit cancer cell proliferation by the induction of cell cycle arrest and apoptosis; thus, suppression of HDAC5 may be a viable option for treating HCC patients.
|
25129440 |
2014 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer.
|
28440397 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Class I histone deacetylases (HDACs) generally promote cell proliferation and tumorigenesis, whereas class IIA HDACs like HDAC4 and HDAC5 may promote or impede cancer development in a tissue-dependent manner.
|
31052182 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Taken together, our data identify HDAC5 as a novel co-factor in N-Myc oncogenesis, and provide the evidence for the potential application of HDAC5 inhibitors in the therapy of N-Myc-induced neuroblastoma and potentially other c-Myc-induced malignancies.
|
23812427 |
2014 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Histone deacetylase 5 (HDAC5), as a member of the class IIa family of HDACs, is frequently dysregulated in human malignancies.
|
30066893 |
2018 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
We found that histone deacetylase 5, a highly expressed histone deacetylase in hepatocellular carcinoma, strengthened the migration and invasion of hepatocellular carcinoma cells under hypoxia but not normoxia condition.
|
28653891 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.
|
27177225 |
2016 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
SMAR1 inhibited Wnt/β-catenin signaling by recruiting Histone deacetylase-5 to β-catenin promoter resulting in reduced cell migration and invasion.
|
29765542 |
2018 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, GO6976, a PKC inhibitor, significantly inhibited not only HGF-induced HDAC5 expression but also cell invasion.
|
20559690 |
2010 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
On the contrary, HDAC5 knockdown largely decreased the proliferation and invasion and enhanced the apoptosis of A549 cells.
|
30066893 |
2018 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.
|
27572323 |
2016 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings demonstrated a novel mechanism underlying the crosstalk between histone deacetylase 5 and hypoxia-inducible factor-1 in hepatocellular carcinoma.
|
28653891 |
2017 |
|
Liver carcinoma
|
0.060 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant expression of several HDACs and copy number gains of HDAC3 and HDAC5 occur in HCC.
|
22322234 |
2012 |
|
Liver carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
The present study reported that the mRNA and protein levels of HDAC5 were up-regulated in human hepatocellular carcinoma (HCC) tissues and cells as shown by quantitative real-time PCR and Western blot.
|
25129440 |
2014 |
|
Liver carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we found that HDAC5 promoted the Six1 expression both at the mRNA and protein levels in HCC cell lines.
|
24706304 |
2014 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
More importantly, Tbx3 directly interacts with HDAC5 via these motifs, and an HDAC inhibitor blocks Tbx3-mediated cell migration and the downregulation of E-cadherin in HCC.
|
30151243 |
2018 |
|
Liver carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
In the present work, we found that the levels of HDAC5 were significantly higher in HCC tissues and cells than in adjacent tissues and normal hepatic cells.
|
29637001 |
2018 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
Expression of histone-modifier genes in breast cancer differed significantly from those in normal tissue (HDAC5, HDAC1, lysine (K)-specific demethylase 4A (KDM4A) and lysine (K)-specific demethylase 6A (KDM6A)).
|
22199269 |
2011 |